Preferred Label : Adenoviral MUC1 Vaccine ETBX-061;
NCIt related terms : ETBX-061; Ad5-MUC1 vaccine;
NCIt definition : A therapeutic cancer vaccine composed of a replication-defective, serotype 5 adenovirus
(Ad5) with the viral genes early 1 (E1), early 2b (E2b), and early 3 (E3) deleted,
and the human glycoprotein mucin 1 (MUC1) encoded, with potential immunostimulating
and antineoplastic activities. Upon subcutaneous administration, the adenoviral MUC1
vaccine ETBX-061 expresses the MUC1 protein. The expressed MUC1 may induce a cytotoxic
T-lymphocyte (CTL)-mediated immune response against tumor cells expressing MUC1, thereby
resulting in both immune-mediated inhibition of tumor cell proliferation and tumor
cell death. Deletion of the E1, E2b and E3 genes from Ad5 prevents anti-adenovirus
immune responses. MUC1, a tumor-associated antigen (TAA) and type I transmembrane
protein, is overexpressed in a variety of tumor types. It plays an important role
in cancer progression and metastasis.;
UNII : 17K7SN702N;
CAS number : 2171550-29-9;
Molecule name : ETBX 061; ETBX-061;
NCI Metathesaurus CUI : CL541479;
Origin ID : C143035;
UMLS CUI : C4684952;
Semantic type(s)
- concept_is_in_subset
- has_target
